Online citations, reference lists, and bibliographies.
← Back to Search

Botulinum Toxin Type A (BOTOX) For Treatment Of Migraine.

W. Binder, M. Brin, A. Blitzer, J. Pogoda
Published 2001 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
An open-label study and 2 double-blind, placebo-controlled studies have provided supporting evidence of botulinum toxin type A (BTX-A) as an effective, well-tolerated treatment for migraine. Observed durations of benefit were consistent with known properties of BTX-A. Findings suggest that response may vary by features of preinjection headaches, such as migraine frequency. The precise mechanism by which BTX-A provides pain relief is hypothesized to be related not only to acetylcholine inhibition but also to a blocking action on the parasympathetic nervous system. Additional studies that control factors likely to be related to response may lead to better understanding of the BTX-A effect on migraine and an optimal treatment protocol.
This paper references
Overview of diagnosis and treatment of migraine
S. Silberstein (1994)
10.1016/0304-3959(94)90048-5
Botulinum toxin in the treatment of myofascial pain syndrome
W. Cheshire (1994)
Migraine. Patterns of healthcare use.
P. Stang (1994)
10.1056/NEJM199201303260516
Therapeutic use of type F botulinum toxin.
C. Ludlow (1992)
10.1016/0304-3959(91)90066-7
Clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofascial inputs
J. Olesen (1991)
10.1002/(SICI)1097-4598(1997)6+<146::AID-MUS10>3.0.CO;2-4
Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology
M. Brin (1997)
10.1001/ARCHOTO.123.4.389
The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients.
A. Blitzer (1997)
10.1016/0306-4522(90)90001-7
Neuropeptide Y Co-Exists with Vasoactive Intestinal Polypeptide and Acetylcholine in Parasympathetic Cerebrovascular Nerves Originating in the Sphenopalatine, OTIC, and Internal Carotid Ganglia of the Rat
N. Suzuki (1990)
10.1002/MDS.870020402
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm
M. Brin (1987)
10.1046/j.1468-1331.2003.00637.x
Parkinson's Disease and Movement Disorders
J. Jankovic (1988)
10.1097/00000542-199403000-00041
Treatment of myofascial pain with botulinum A toxin.
M. Acquadro (1994)
10.1046/j.1526-4610.2000.00066.x
Botulinum Toxin Type A as a Migraine Preventive Treatment
S. Silberstein (2000)
10.1016/0014-5793(90)80582-4
Ca2+‐dependent noradrenaline release from permeabilised PC 12 cells is blocked by botulinum neurotoxin A or its light chain
C. McInnes (1990)
10.3109/00016489309135834
Botulinum A toxin effects on rat jaw muscle spindles.
G. Filippi (1993)
10.1046/j.1526-4610.1998.3806468.x
Botulinum Toxin A, Adjunctive Therapy for Refractory Headaches Associated With Pericranial Muscle Tension
A. Wheeler (1998)
10.1046/j.1526-4610.1998.3805366.x
Headache and Facial Pain Responsive to Botulinum Toxin: An Unusual Presentation of Blepharospasm
S. Johnstone (1998)
10.1046/j.1526-4610.1997.3704253.x
Botulinum Toxin Injection for Cervicogenic Headache
D. Hobson (1997)
10.1016/0306-4522(87)90094-7
Selective location of acceptors for botulinum neurotoxin a in the central and peripheral nervous systems
J. Black (1987)
Overview of treatment diagnosis and of migraine
S. Silberstein (1994)
10.1016/0223-5234(87)90042-0
Cellular and molecular basis of cholinergic function
M. Dowdall (1987)
10.1523/JNEUROSCI.15-01-00520.1995
Calcitonin gene-related peptide: possible role in formation and maintenance of neuromuscular junctions
C. Sala (1995)
10.1136/jnnp.59.6.601
Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.
G. Sheean (1995)
10.1111/j.1526-4610.1994.hed3408458.x
Tension Headache: Botulinum Toxin Paralysis of Temporal Muscles
J. A. Zwart (1994)
10.1113/jphysiol.1936.sp003434
The technique of suprarenalectomy in the guinea‐pig and the survival period and cause of death of guinea‐pigs after bilateral suprarenalectomy
H. Simmons (1936)
10.1002/MUS.880180214
Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp
R. Kaji (1995)
10.1111/j.1468-1331.1997.tb00300.x
Cytokines and soluble IL‐4 in patients with acute optic neuritis and multiple sclerosis
F. Sellebjerg (1997)
10.1016/0002-9394(88)90016-5
Negative antibody response to long-term treatment of facial spasm with botulinum toxin.
R. Gonnering (1988)
10.1016/s0194-5998(95)70212-1
Rhinorrhea is decreased in dogs after nasal application of botulinum toxin.
C. M. Shaari (1995)
10.1002/ANA.410160202
The neurobiology of vascular head pain
M. Moskowitz (1984)
RECENT ADVANCES IN MIGRAINE MANAGEMENT
Cady Rk (1993)
10.1002/MDS.870080411
Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A
P. E. Greene (1993)
10.1067/mhn.2000.110960
Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study
W. Binder (2000)
10.1212/WNL.45.9.1743
Response and immunoresistance to botulinum toxin injections
J. Jankovic (1995)
10.1111/J.1432-1033.1987.TB11494.X
Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes.
J. Sánchez-Prieto (1987)
10.1016/0014-2999(89)90229-X
Effects of botulinum A toxin on presynaptic modulation of evoked transmitter release.
R. Nakov (1989)
10.1016/0928-4257(94)90086-8
Inhibition of neurotransmitter release by clostridial neurotoxins correlates with specific proteolysis of synaptosomal proteins
J. Blasi (1994)
10.1212/WNL.45.3.506
Comparison of Therapeutic Efficacies of Type A and F Botulinum Toxins for Blepharospasm
T. Mezaki (1995)
Migraine prevalence. A review of population-based studies.
W. Stewart (1994)
10.1016/0006-8993(85)90535-9
Extracranial vasodilatation mediated by vasoactive intestinal polypeptide (VIP)
P. Goadsby (1985)
10.1046/j.1526-4610.1996.3606352.x
The Placebo Effect in Acute Headache Management: Ketorolac, Meperidine, and Saline in the Emergency Department
R. Harden (1996)
10.1111/j.1471-4159.1988.tb02482.x
Characterization of the Inhibitory Action of Botulinum Neurotoxin Type A on the Release of Several Transmitters from Rat Cerebrocortical Synaptosomes
A. C. Ashton (1988)
10.1002/ANA.410280213
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
P. J. Goadsby (1990)
10.1002/MDS.870130128
Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections
C. Sankhla (1998)
10.1046/j.1526-4610.2000.00044.x
Treatment of Tension‐type Headache With Botulinum Toxin Type A: A Double‐Blind, Placebo‐Controlled Study
J. Rollnik (2000)
10.1002/(SICI)1097-4598(1997)6+<129::AID-MUS9>3.0.CO;2-B
Botulinum toxin: Historical perspective and potential new indications
J. Jankovic (1997)
10.1097/00019052-199406000-00016
Pathophysiology of migraine and tension-type headache.
A. Zagami (1994)
10.1016/s0021-9258(19)36614-1
Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action.
H. McMahon (1992)



This paper is referenced by
10.1016/B978-1-4160-4928-9.00005-6
Chapter 5 – Immune Recognition of Botulinum Neurotoxins A and B: Molecular Elucidation of Immune Protection Against the Toxins
M. Atassi (2009)
10.1016/B978-0-7216-0334-6.50046-7
chapter 42 – Migraine Headache
S. Diamond (2007)
10.1016/J.MOLIMM.2005.01.016
Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A.
M. Atassi (2005)
10.1016/j.imbio.2011.08.009
Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
M. Atassi (2012)
10.1002/JMR.802
A peptide‐based immunoassay for antibodies against botulinum neurotoxin A
M. Atassi (2007)
10.1016/J.MOLIMM.2006.03.011
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
B. Z. Dolimbek (2007)
Estudi de les diferències psicopatològiques en pacients amb mal de cap crònic, episòdic i control. Relació amb la resposta al tractament
I. S. Matavera (2010)
10.3109/9781841847559.001
Pharmacology, Immunology and Current Developments
K. Aoki (2006)
10.1016/j.jneuroim.2014.04.015
Reduction of established antibody responses against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol peptide conjugates
M. Atassi (2014)
10.1007/978-3-319-01875-1_11
Headaches, Migraine, and Cluster Headache
Ghabi A. Kaspo (2014)
10.1097/SPV.0B013E318177EB4F
Botulinum Toxin for Lower Urinary Tract Symptoms in Women
L. Rickey (2008)
10.1007/S11916-003-0078-1
Is there a role for botulinum toxin in the treatment of migraine?
S. Evers (2003)
10.1016/j.imbio.2010.12.009
Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies.
M. Atassi (2011)
10.1111/J.1526-4637.2006.00084.X
Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpal tunnel syndrome.
B. Breuer (2006)
10.1016/j.imlet.2011.02.002
Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates.
B. Z. Dolimbek (2011)
10.1016/J.AJOG.2006.03.108
Botulinum toxin: from life-threatening disease to novel medical therapy.
S. Mahajan (2007)
10.1002/9781118661833.CH25
Exciting New Uses of Botulinum Toxin Type A: Dermatology/Dermatologic Surgery and Beyond
D. Martin (2017)
10.1016/J.CLINDERMATOL.2003.11.013
Botox: beyond wrinkles.
J. Carruthers (2004)
10.1016/j.molimm.2008.06.031
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment.
M. Atassi (2008)
10.1021/bi201322c
Location of the synaptosome-binding regions on botulinum neurotoxin B.
B. Z. Dolimbek (2012)
10.1016/j.jneumeth.2005.05.026
Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: A new assay for blocking and non-blocking antibodies
Takahiro Maruta (2006)
10.1016/J.MOLIMM.2007.08.007
Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin.
B. Z. Dolimbek (2008)
Semantic Scholar Logo Some data provided by SemanticScholar